International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 44

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 44

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 44

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas.
La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

Proposed INN (Latin, English, French, Spanish)	*Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula*
DCI Proposée	*Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée*
DCI Propuesta	*Nombre químico o descripción: Acción y uso: Fórmula empírica Número de registro del CAS: Fórmula desarrollada*

adalimumabum

adalimumab — immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7k-chain, dimer

adalimumab — immunoglobuline G1, anti-(facteur a de nécrose tumorale humain) (chaîne lourde de l'anticorps monoclonal humain D2E7), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain D2E7

adalimumab — inmunoglobulina G1 (anti-factor α de necrosis tumoral humano), dímero del disulfuro de la cadena pesada D2E7 monoclonal humana con la cadena κ D2E7 monoclonal humana

adrogolidum

adrogolide — (5a*R*,11b*S*)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[*f*]thieno[2,3-*c*]quinoline-9,10-diol diacetate (ester)

adrogolide — diacétate de (5a*R*,11b*S*)-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[*f*]thieno=[2,3-*c*]quinoléine-9,10-diyle

adrogolida — diacetato (éster)de (5a*R*,11b*S*)-4,5,5a,6,7,11b-hexahidro-2-propilbenzo=[*f*]tieno[2,3-*c*]quinolina-9,10-dilo

$C_{22}H_{25}NO_4S$



alemcinalum

alemcinal — 8,9-didehydro-*N*-demethyl-9-deoxo-4'',6,12-trideoxy-6,9-epoxy-*N*-ethylerythromycin

alemcinal — (2*R*,3*S*,4*R*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-5-éthyl-11-[[3-(éthylméthylamino)-3,4,6-tridésoxy-β-D-*xylo*-hexopyranosyl]oxy]-3-hydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3-*C*-méthyl-3-*O*-méthyl-2,4,6-tridésoxy-α-L-*erythro*-hexopyranosyl)oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

alemcinal

8,9-dideshidro-*N*-desmetil-9-desoxo-4",6,12-tridesoxi-6,9-epoxi-*N*-etileritromicina

$C_{38}H_{67}NO_{10}$



altiniclinum

altinicline

(-)-5-ethynylnicotine

altinicline

(-)-3-éthynyl-5-[(2*S*)-1-méthylpyrrolidin-2-yl]pyridine

altiniclina

(-)-5-etinilnicotina

$C_{12}H_{14}N_2$



amiglumidum

amiglumide

(*R*)-4-(2-naphthamido)-*N*,*N*-dipentylglutaramic acid

amiglumide

acide (4*R*)-5-(dipentylamino)-4-[(naphtalén-2-ylcarbonyl)amino]-5-oxopentanoïque

amiglumida

(*R*)-4-(2-naftamido)-*N*,*N*-dipentilglutarámico

$C_{26}H_{36}N_2O_4$



anisperimusum

anisperimus [(6-guanidinohexyl)carbamoyl]methyl [4-[[(*R*)-3-aminobutyl]amino]butyl]= carbamate

anispérimus [4-[[(3*R*)-3-aminobutyl]amino]butyl]carbamate de 2-[(6-guanidinohexyl)amino]-2-oxoéthyle

anisperimus [4-[[(*R*)-3-aminobutil]amino]butil]carbamato de [(6-guanidinohexil)carbamoil]metilo

$C_{18}H_{39}N_7O_3$



ataquimastum

ataquimast 1-ethyl-3-(methylamino)-2(1*H*)-quinoxalinone

ataquimast 1-éthyl-3-(méthylamino)quinoxalin-2(1*H*)-one

ataquimast 1-etil-3-(metilamino)-2(1*H*)-quinoxalinona

$C_{11}H_{13}N_3O$



axitiromum

axitirome ethyl (±)-4'-[[α-(*p*-fluorophenyl)-α,4-dihydroxy-*m*-tolyl]oxy]-3',5'-dimethyloxanilate

axitirome [[4-[3-[(*RS*)-(4-fluorophényl)hydroxyméthyl]-4-hydroxyphénoxy]-3,5-diméthylphényl]amino]oxoacétate d' éthyle

axitiromo (±)-4'-[[α-(*p*-fluorofenil)-α,4-dihidroxi-*m*-tolil]oxi]-3',5'-dimetiloxanilato de etilo

$C_{25}H_{24}FNO_6$



and enantiomer
et énantiomère
y enantiómero

bilastinum

bilastine — *p*-[2-[4-[1-(2-ethoxyethyl)-2-benzimidazolyl]piperidino]ethyl]-α-methylhydratropic acid

bilastine — acide 2-[4-[2-[4-[1-(2-éthoxyéthyl)-1*H*-benzimidazol-2-yl]pipéridin-1-yl]éthyl]phényl]-2-méthylpropanoïque

bilastina — ácido *p*-[2-[4-[1-(2-etoxietil)-2-bencimidazolil]piperidino]etil]-α-metilhidratrópico

$C_{28}H_{37}N_3O_3$



binetrakinum

binetrakin — interleukin 4 (human)

binétrakine — interleukine 4 humaine

binetrakina — interleuquina 4 (humana)



cangrelorum

cangrelor — *N*-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene)diphosphonic acid

cangrélor — monoanhydride dichlorométhylènediphosphonique *N*-[2-(méthylsulfanyl) éthyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]-5'-adénylique

cangrelor — monoanhidrido del ácido *N*-[2-(metiltio)etil]-2-[(3,3,3-trifluoropropil)tio]-5'-adenílico con ácido (diclorometileno)difosfónico

$C_{17}H_{25}Cl_2F_3N_5O_{12}P_3S_2$



cetuximabum

cetuximab — immunoglobulin G 1 (human-mouse monoclonal C225 γ1-chain anti-human epidermal growth factor receptor), disulfide with human-mouse monoclonal C225 κ-chain, dimer

cétuximab — immunoglobuline G1, anti-(récepteur du facteur de croissance humain de l'épiderme) (chaîne γ1 de l'anticorps monoclonal chimérique homme-souris C225), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-souris C225

cetuximab — inmunoglobulina G 1, anti-(receptor del factor humano de crecimiento de la epidermis)(cadena γ1-del anticuerpo monoclonal quimérico hombre-ratón C225), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-ratón C225

cilomilastum

cilomilast — *cis*-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid

cilomilast — acide *cis*-4-cyano-4-[3-(cyclopentyloxy)-4-méthoxyphényl]cyclohexanecarboxylique

cilomilast — ácido *cis*-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxílico

$C_{20}H_{25}NO_4$



conivaptanum

conivaptan — 4''-[(4,5-dihydro-2-methylimidazo[4,5-*d*][1]benzazepin-6(1*H*)-yl)carbonyl]-2-biphenylcarboxanilide

conivaptan — *N*-[4-[(2-méthyl-4,5-dihydroimidazo[4,5-*d*][1]benzaépin-6(1*H*)-yl)carbonyl]phényl]biphényle-2-carboxamide

conivaptán — 4''-[(4,5-dihidro-2-metilimidazo[4,5-*d*][1]benzazepin-6(1*H*)-il)carbonil]-2-bifenilcarboxanilida

$C_{32}H_{26}N_4O_2$



crobenetinum

crobenetine	(2*R*,6*S*)-3-[(2*S*)-2-(benzyloxy)propyl]-1,2,3,4,5,6-hexahydro-6,11,11-trimethyl-2,6-methano-3-benzazocin-10-ol
crobénétine	(2*R*,6*S*)-3-[(2*S*)-2-(benzyloxy)propyl]-6,11,11-triméthyl-1,2,3,4,5,6-hexahydro-2,6-méthano-3-benzazocin-10-ol
crobenetina	(2*R*,6*S*)-3-[(2*S*)-2-(benciloxi)propil]-1,2,3,4,5,6-hexahidro-6,11,11-trimetil-2,6-metano-3-benzazocin-10-ol

$C_{25}H_{33}NO_2$



cystinum

cystine	L-cystine
cystine	L-cystine
cistina	L-cistina

$C_6H_{12}N_2O_4S_2$



darusentanum

darusentan	(+)-(*S*)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropionic acid
darusentan	(+)-acide (2*S*)-2-(4,6-diméthoxypyrimidin-2-yloxy)-3-méthoxy-3,3-diphénylpropanoïque
darusentán	ácido (+)-(*S*)-2-[(4,6-dimetoxi-2-pirimidinil)oxi]-3-metoxi-3,3-difenilpropiónico

$C_{22}H_{22}N_2O_6$



donitriptanum

donitriptan — 1-[[[3-(2-aminoethyl)indol-5-yl]oxy]acetyl]-4-(*p*-cyanophenyl)piperazine

donitriptan — 1-[2-[[3-(2-aminoéthyl)-1*H*-indol-5-yl]oxy]acétyl]-4-(4-cyanophényl)pipérazine

donitriptán — 1-[[[3-(2-aminoetil)indol-5-il]oxi]acetil]-4-(*p*-cianofenil)piperazina

$C_{23}H_{25}N_5O_2$



doxercalciferolum

doxercalciferol — (5*Z*,7*E*,22*E*)-9,10-secoergosta-5,7,10(19),22-tetraene-1α,3β-diol

doxercalciférol — (5*Z*,7*E*,22*E*)-9,10-sécoergosta-5,7,10(19),22-tétraène-1α,3β-diol

doxercalciferol — (5*Z*,7*E*,22*E*)-9,10-secoergosta-5,7,10(19),22-tetraeno-1α,3β-diol

$C_{28}H_{44}O_2$



emfilerminum

emfilermin — leukemia-inhibiting factor (human)

emfilermine — facteur d'inhibition leucémique humain

emfilermina — factor inhibidor de leucemia (humano)

SPLPITPVNA TCAIRHPCHN NLMNQIRSQL AQLNGSANAL
FILYYTAQGE PFPNNLDKLC GPNVTDFPPF HANGTEKAKL
VELYRIVVYL GTSLGNITRD QKILNPSALS LHSKLNATAD
ILRGLLSNVL CRLCSKYHVG HVDVTYGPDT SGKDVFQKKK
LGCQLLGKYK QIIAVLAQAF

emivirinum

emivirine — 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil

émivirine — 6-benzyl-1-(éthoxyméthyl)-5-(1-méthyléthyl)pyrimidine-2,4(1*H*,3*H*)-dione

emivirina — 6-bencil-1-(etoximetil)-5-isopropiluracilo

$C_{17}H_{22}N_2O_3$



entecavirum

entecavir — 9-[(1*S*,3*R*,4*S*)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine

entécavir — 2-amino-9-[(1*S*,3*R*,4*S*)-4-hydroxy-3-(hydroxyméthyl)-2-méthylènecyclopentyl]-1,9-dihydro-6*H*-purin-6-one

entecavir — 9-[(1*S*,3*R*,4*S*)-4-hidroxi-3-(hidroximetil)-2-metilenociclopentil]guanina

$C_{12}H_{15}N_5O_3$



epitumomabum

epitumomab — mouse IgG 1 monoclonal antibody which binds the human muc-1 gene product

épitumomab — immunoglobuline G2a, anti-(antigène CD20 humain) (chaîne γ2a de l'anticorps monoclonal de souris B1R1), dimère du disulfure avec la chaîne λ de l'anticorps monoclonal de souris B1R1

epitumomab — inmunoglobulina G2a, anti-(antígeno CD20 humano) (cadena γ2a del anticuerpo monoclonal de ratón B1R1), dímero del disulfuro con la cadena λ del anticuerpo monoclonal de ratón B1R1

epratuzumabum

epratuzumab — immunoglobulin G (human-mouse monoclonal IMMU-hLL2 γ-chain anti-human antigen CD22), disulfide with human-mouse monoclonal IMMU-hLL2 κ-chain, dimer

épratuzumab — immunoglobuline G, anti-(antigène CD22 humain) (chaîne γ de l'anticorps monoclonal de souris IMMU-hLL2 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris IMMU-hLL2 humanisé

epratuzumab — inmunoglobulina G, anti-(antígeno CD22 humano)(cadena γ del anticuerpo monoclonal humanizado de ratón IMMU-hLL2) dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón IMMU-hLL2

eptapironum

eptapirone — 4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-*as*-triazine-3,5(2*H*,4*H*)-dione

eptapirone — 4-méthyl-2-[4-[4-(pyrimidin-2-yl)pipérazin-1-yl]butyl]-1,2,4-triazine-3,5(2*H*,4*H*) dione

eptapirona — 4-metil-2-[4-[4-(2-pirimidinil)-1-piperazinil]butil]-*as*-triazina-3,5(2H,4H)-diona

$C_{16}H_{23}N_7O_2$



escitalopramum

escitalopram — (+)-(*S*)-1-[3-(dimethylamino)propyl]-1-(*p*-fluorophenyl)-5-phthalancarbonitrile

escitalopram — (+)-(1*S*)-1-[3-(diméthylamino)propyl]-1-(4-fluorophényl)-1,3-dihydroisobenzofurane-5-carbonitrile

escitalopram — (+)-(*S*)-1-[3-(dimetilamino)propil]-1-(*p*-fluorofenil)-5-ftalancarbonitrilo

$C_{20}H_{21}FN_2O$



evernimicinum

evernimicin

O-(1*R*)-2,3-*O*-methylene-4-*O*-(6-methyl-β-resorcyloyl)-D-xylopyranosylidene-(1 3-4)-α-L-lyxopyranosyl *O*-2,3,6-trideoxy-3-*C*-methyl-4-*O*-methyl-3-nitro-α-L-*arabino*-hexopyranosyl-(1→3)-*O*-2,6-dideoxy-4-*O*-(3,5-dichloro-6-methoxy-4,2-cresotoyl)-β-D-*arabino*-hexopyranosyl-(1→4)-*O*-(1*R*)-2,6-dideoxy-D-*arabino*-hexopyranosylidene-(1→3-4)-*O*-6-deoxy-3-*C*-methyl-β-D-mannopyranosyl-(1→3)-*O*-6-deoxy-4-O-methyl-β-D-galactopyranosyl-(1→4)-2,6-di-*O*-methyl-β-D-mannopyranoside

évernimicine

O-3-*C*-méthyl-4-*O*-méthyl-3-nitro-2,3,6-tridésoxy-α-L-*arabino*-hexopyranosyl-(1→3)-*O*-4-*O*-(3,5-dichloro-4-hydroxy-2-méthoxy-6-méthylbenzoyl)-2,6-didésoxy-β-D-*arabino*-hexopyranosyl-(1→4)-*O*-(1*R*)-2,6-didésoxy-D-*arabino*-hexopyranosylidène-(1→3-4)-*O*-3-*C*-méthyl-6-désoxy-β-D-mannopyranosyl-(1→3)-*O*-4-*O*-méthyl-6-désoxy-β-D-galactopyranosyl-(1→4)-2,6-di-*O*-méthyl-β-D-mannopyranoside de *O*-(1*R*)-4-*O*-(2,4-dihydroxy-6-méthylbenzoyl)-2,3-*O*-méthylène-D-xylopyranosylidène-(1→3-4)-α-L-lyxopyranosyle

evernimicina

O-2,3,6-tridesoxi-3-C-metil-4-*O*-metil-3-nitro-α-L-*arabino*-hexopiranosil-(1→3)-*O*-2,6-didesoxi-4-*O*-(3,5-dicloro-6-metoxi-4,2-cresotoil)-β-D-*arabino*-hexopiranosil-(1→4)-*O*-(1R)-2,6-didesoxi-D-*arabino*-hexopiranosilideno-(1→3-4)-*O*-6-desoxi-3-C-metil-β-D-manopiranosil-(1→3)-*O*-6-desoxi-4-*O*-metil-β-D-galactopiranosil-(1→3)-2,6-di-*O*-metil-β-D-manopiranósido de *O*-(1R)-2,3-*O*-metileno-4-*O*-(6-metil-β-resorciloil)-D-xilopiranosilideno-(1→3-4)-α-L-lixopiranosilo

$C_{70}H_{97}Cl_2NO_{38}$



everolimusum

everolimus

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3*H*-pyrido[2,1-*c*][1,4]=oxaazacyclohentriacontine-1,5,11,28,29(4*H*,6*H*,31*H*)-pentone

évérolimus

(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*E*,30*S*,32*S*,35*R*)-1,18-dihydroxy-12-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-hydroxyéthoxy)-3-méthoxycyclohexyl]-1-méthyléthyl]-19,30-diméthoxy-15,17,21,23,29,35-hexaméthyl-11,36-dioxa-4-azatricyclo[30.3.1.$0^{4,9}$]hexatriaconta-16,24,26,28-tétraène-2,3,10,14,20-pentone

everolimus

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahidro-9,27-dihidroxi-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-hidroxietoxi)-3-metoxiciclohexil]-1-metiletil]-10,21-dimetoxi-6,8,12,14,20,26-hexametil-23,27-epoxi-3*H*-pirido[2,1-*c*][1,4]oxaazaciclohentriacontina-1,5,11,28,29(4*H*,6*H*,31*H*)-pentona

$C_{53}H_{83}NO_{14}$



ezlopitantum

ezlopitant

(2*S*,3*S*)-2-(diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]=quinuclidine

ezlopitant

(2*S*,3*S*)-2-(diphénylméthyl)-*N*-[2-méthoxy-5-(1-méthyléthyl)benzyl]-1-azabibyclo[2.2.2]octan-3-amine

ezlopitant

(2*S*,3*S*)-2-(difenilmetil)-3-[(5-isopropil-2-metoxibencil)amino]quinuclidina

$C_{31}H_{38}N_2O$



fiduxosinum

fiduxosin — 8-phenyl-3-[4-[(3a*R*,9b*R*)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano=[3,4-*c*]pyrrol-2(3*H*)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione

fiduxosine — 3-[4-[(3a*R*,9b*R*)-9-méthoxy-1,3a,4,9b-tétrahydro[1]benzopyrano[3,4-*c*]pyrrol-2(3*H*)-yl]butyl]-8-phénylpyrazino[2',3':4,5]thiéno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione

fiduxosina — 8-fenil-3-[4-[(3a*R*,9b*R*)-1,3a,4,9b-tetrahidro-9-metoxi[1]benzopirano[3,4-*c*]=pirrol-2(3*H*)-il]butil]pirazino[2',3':4,5]tieno[3,2-*d*]pirimidina-2,4(1*H*,3*H*)-diona

$C_{30}H_{29}N_5O_4S$



figopitantum

figopitant — (*S*)-*N*-[bis(3,5-trifluoromethyl)phenethyl]-4-(cyclopropylmethyl)-*N*-methyl-α-phenyl-1-piperazineacetamide

figopitant — (2*S*)-*N*-[2-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-[4-(cyclopropylméthyl)=pipérazin-1-yl]-*N*-méthyl-2-phénylacétamide

figopitant — (*S*)-*N*-[bis(3,5-trifluorometil)fenetil]-4-(ciclopropilmetil)-*N*-metil-α-fenil-1-piperazinaacetamida

$C_{27}H_{31}F_6N_3O$



implitapidum

implitapide (αS)-α-[α-(2,4-dimethyl-9*H*-pyrido[2,3-*b*]indol-9-yl)-*p*-tolyl]-*N*-[(α*R*)-α-(hydroxymethyl)benzyl]cyclopentaneacetamide

implitapide (2*S*)-2-cyclopentyl-2-[4-[(2,4-diméthyl-9*H*-pyrido[2,3-*b*]indol-9-yl)méthyl]phényl]-*N*-[(1*R*)-2-hydroxy-1-phényléthyl]acétamide

implitapida (αS)-α-[α-(2,4-dimetil-9*H*-pirido[2,3-*b*]indol-9-il)-*p*-tolil]-*N*-[(α*R*)-α-(hidroximetil)bencil]ciclopentanoacetamida

$C_{35}H_{37}N_3O_2$



irampanelum

irampanel 5-[*o*-[2-(dimethylamino)ethoxy]phenyl]-3-phenyl-1,2,4-oxadiazole

irampanel *N*,*N*-diméthyl-2-[2-(3-phényl-1,2,4-oxadiazol-5-yl)phénoxy]éthanamine

irampanel 5-[o-[2-(dimetilamino)etoxi]fenil]-3-fenil-1,2,4-oxadiazol

$C_{18}H_{19}N_3O_2$



irofulvenum

irofulven (*R*)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-[5*H*]inden]-7'(6'*H*)-one

irofulvène (6'*R*)-6'-hydroxy-3'-(hydroxyméthyl)-2',4',6'-triméthylspiro[cyclopropane-1,5'-[5*H*]indén]-7'(6'*H*)-one

irofulveno (R)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilspiro[ciclopropano-1,5'-[5*H*]inden]-7'(6'*H*)-ona

$C_{15}H_{18}O_3$



itriglumidum

itriglumide — (*R*)-2'-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4',6'-dimethyl-3-(1-naphthyl)glutaranilic acid

itriglumide — acide (3*R*)-5-[[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-diméthylphényl]amino]-3-(naphtalén-1-yl)-5-oxopentanoïque

itriglumida — ácido (*R*)-2'-(8-azaspiro[4.5]dec-8-ilcarbonil)-4',6'-dimetil-3-(1-naftil)glutaranílico

$C_{33}H_{38}N_2O_4$



laniceminum

lanicemine — (+)-2-[(*S*)-β-aminophenethyl]pyridine

lanicémine — (+)-(1*S*)-1-phényl-2-(pyridin-2-yl)éthanamine

lanicemina — (+)-2-[(*S*)-β-aminofenetil]piridina

$C_{13}H_{14}N_2$



lusaperidonum

lusaperidone — 3-[2-(3,4-dihydrobenzofuro[3,2-*c*]pyridin-2(1*H*)-yl)ethyl]-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

lusapéridone — 3-[2-(3,4-dihydrobenzofuro[3,2-*c*]pyridin-2(1*H*)-yl)éthyl]-2-méthyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

lusaperidona — 3-[2-(3,4-dihidrobenzofuro[3,2-*c*]piridin-2(1*H*)-il)etil]-2-metil-4*H*-pirido[1,2-*a*]pirimidin-4-ona

$C_{22}H_{21}N_3O_2$



metreleptinum

metreleptin — *N*-methionylleptin (human)

métréleptine — *N*-méthionylleptine humaine

metreleptina — *N*-metionileptina (humana)

$C_{714}H_{1167}N_{191}O_{221}S_6$

M

VPIQKVQDDT KTLIKTIVTR INDISHTQSV SSKQKVTGLD

FIPGLHPILT LSKMDQTLAV YQQILTSMPS RNVIQISNDL

ENLRDLLHVL AFSKSCHLPW ASGLETLDSL GGVLEASGYS

TEVVALSRLQ GSLQDMLWQL DLSPGC

mitumomabum

mitumomab — immunoglobulin G2b (mouse monoclonal BEC2 γ2b-chain anti-GD3 ganglioside), disulfide with mouse monoclonal BEC2 κ-chain, dimer

mitumomab — immunoglobuline G2b, anti-(ganglioside GD3) (chaîne γ2b de l'anticorps monoclonal de souris BEC2), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BEC2

mitumomab — inmunoglobulina G2b,anti-(gangliósido GD3)(cadena γ2b del anticuerpo monoclonal de ratón BEC2) dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón BEC2

motexafinum

motexafin — 9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanol

motéxafine — 3,3'-[9,10-diéthyl-20,21-bis[2-[2-(2-méthoxyéthoxy)éthoxy]éthoxy]-4,15-diméthyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloicosène-5,14-diyl]dipropan-1-ol

motexafina — 9,10-dietil-20,21-bis[2-[2-(2-metoxietoxi)etoxi]etoxi]-4,15-dimetil-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacicloeicosina-5,14-dipropanol

$C_{48}H_{67}N_5O_{10}$



nebostinelum

nebostinel (*S*)-4-amino-*N*-(4,4-dimethylcyclohexyl)glutaramic acid

nébostinel acide (4*S*)-4-amino-5-[(4,4-diméthylcyclohexyl)amino]-5-oxopentanoïque

nebostinel ácido (*S*)-4-amino-*N*-(4,4-dimetilciclohexil)glutarámico

$C_{13}H_{24}N_2O_3$



onerceptum

onercept glycoprotein TNF-BP (tumor necrosis factor-binding protein) (human disulfide variant 1)

onercept 20-180-récepteur 1 humain du facteur de nécrose tumorale, protéine glycosylée (partie du domaine extracellulaire)

onercept glicoproteína TNF-BP (proteína de unión al factor de necrosis tumoral)(disulfuro de la variante 1 humana)

$C_{753}H_{1156}N_{228}O_{247}S_{25}$



pegvisomantum

pegvisomant — 18-L-aspartic acid-21-L-asparagine-120-L-lysine-167-L-asparagine-168-L-alanine-171-L-serine-172-L-arginine-174-L-serine-179-L-threonine growth hormone (human), reaction product with polyethylene glycol

pegvisomant — [18-acide L-aspartique-21-L-asparagine-120-L-lysine-167-L-asparagine-168-L-alanine-171-L-sérine-172-L-arginine-174-L-sérine-179-L-thréonine] hormone humaine de croissance combinée à du polyéthylène glycol

pegvisomant — producto de reacción con polietilenglicol de la 18-ácido-L-aspártico 21-L-asparagina-120-L-lisina-167-L-asparagina-168-L-alanina-171-L-serina-172-L-arginina-174-L-serina-179-L-treoninahormona del crecimiento (humana)

*FPTIPLSRLF DNAMLRADRL NQLAFDTYQE FEEAYIPKEQ
KYSFLQNPQT SLCFSESIPT PSNREETQQ*K SNLELLRISL
LLIQSWLEPV QFLRSVFANS LVYGASDSNV YDLLKDLEE*K
IQTLMGRLED GSPRTGQIF*K QTYS*KFDTNS HNDDALL*KNY
GLLYCFNADM SRVSTFLRTV QCRSVEGSCG F

* pegylation sites
* sites de pégylation
* posiciónes de pegilación

perflexanum

perflexane — tetradecafluorohexane

perflexane — tétradécafluorohexane

perflexano — tetradecafluorohexano

C_6F_{14}



perflutrenum

perflutren — octafluoropropane

perflutrène — octafluoropropane

perflutreno — octafluoropropano

C_3F_8



pinokalantum

pinokalant — (±)-3,4-dihydro-6,7-dimethoxy-α-phenyl-*N*,*N*-bis(2,3,4-trimethoxyphenethyl)-1-isoquinolineacetamide

pinokalant — (2*RS*)-2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-1-yl)-2-phényl-*N*,*N*-bis[2-(2,3,4-triméthoxyphényl)éthyl]acétamide

pinokalant — (±)-3,4-dihidro-6,7-dimetoxi-α-fenil-*N*,*N*-bis(2,3,4-trimetoxifenetil)-1-isoquinolinacetamida

$C_{41}H_{48}N_2O_9$



and enantiomer
et énantiomère
y enantiómero

posaconazolum

posaconazole — 4-[*p*-[4-[*p*-[[(3*R*,5*R*)-5-(2,4-difluorophenyl)tetrahydro-5-(1*H*-1,2,4-triazol-1-ylmethyl)-3-furyl]methoxy]phenyl]-1-piperazinyl]phenyl]-1-[(1*S*,2*S*)-1-ethyl-2-hydroxypropyl]-Δ^2-1,2,4-triazolin-5-one

posaconazole — 4-[4-[4-[4-[[(3*R*,5*R*)-5-(2,4-difluorophényl)-5-(1*H*-1,2,4-triazol-1-ylméthyl)=tétrahydrofuran-3-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-2-[(1*S*,2*S*)-1-éthyl-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one

posaconazol — 4-[*p*-[4-[*p*-[[(3*R*,5*R*)-5-(2,4-difluorofenil)tetrahidro-5-(1*H*-1,2,4-triazol-1-ilmetil)-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1*S*,2*S*)-1-etil-2-hidroxipropil]-D^2-1,2,4-triazolin-5-ona

$C_{37}H_{42}F_2N_8O_4$



prinomastatum

prinomastat — (*S*)-2,2-dimethyl-4-[[*p*-(4-pyridyloxy)phenyl]sulfonyl]-3-thiomorpholinecarbohydroxamio acid

prinomastat — (3*S*)-*N*-hydroxy-2,2-diméthyl-4-[[4-(pyridin-4-yloxy)phényl]sulfonyl]=thiomorpholine-3-carboxamide

prinomastat — ácido (*S*)-2,2-dimetil-4-[[*p*-(4-piridiloxi)fenil]sulfonil]-3-tiomorfolinacarbohidroxámico

$C_{18}H_{21}N_3O_5S_2$



pumafentrinum

pumafentrine — (-)-*p*-[(4a*R**,10b*S**)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[*c*][1,6]naphthyridin-6-yl]-*N*,*N*-diisopropylbenzamide

pumafentrine — (-)-4-[(4a*R**,10b*S**)-9-éthoxy-8-méthoxy-2-méthyl-1,2,3,4,4a,10b-hexahydrobenzo[*c*][1,6]naphtyridin-6-yl]-*N*,*N*-bis(1-méthyléthyl)benzamide

pumafentrina — (-)-*p*-[(4a*R**,10b*S**)-9-etoxi-1,2,3,4,4a,10b-hexahidro-8-metoxi-2-metilbenzo[*c*][1,6]naftiridina-6-il]-*N*,*N*-diisopropilbenzamida

$C_{29}H_{39}N_3O_3$



relcovaptanum

relcovaptan — (2*S*)-1-[[(2*R*,3*S*)-5-chloro-3-(*o*-chlorophenyl)-1-[(3,4-dimethoxyphenyl)=sulfonyl]-3-hydroxy-2-indolinyl]carbonyl]-2-pyrrolidinecarboxamide

relcovaptan — (2*S*)-1-[[(2*R*,3*S*)-5-chloro-3-(2-chlorophényl)-1-[(3,4-diméthoxyphényl)=sulfonyl]-3-hydroxy-2,3-dihydro-1*H*-indol-2-yl]carbonyl]pyrrolidine-2-carboxamide

relcovaptán — (2*S*)-1-[[(2*R*,3*S*)-5-cloro-3-(o-clorofenil)-1-[(3,4-dimetoxifenil)sulfonil]-3-hidroxi-2-indolinil]carbonil]-2-pirrolidinacarboxamida

$C_{28}H_{27}Cl_2N_3O_7S$



repiferminum

repifermin — 33-172-keratinocyte growth factor 2 (human)

répifermine — 33-172-facteur 2 humain de croissance du kératinocyte

repifermina — 33-172-factor 2 de crecimiento de queratinocitos (humano)

$C_{723}H_{1131}N_{209}O_{204}S_5$

SYNHLQGDVR WRKLFSFTKY FLKIEKNGKV SGTKKENCPY
SILEITSVEI GVVAVKAINS NYYLAMNKKG KLYGSKEFNN
DCKLKERIEE NGYNTYASFN WQHNGRQMYV ALNGKGAPRR
GQKTRRKNTS AHFLPMVVHS

resiquimodum

resiquimod — 4-amino-2-(ethoxymethyl)-α,α-dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol

résiquimod — 1-[4-amino-2-(éthoxyméthyl)-1*H*-imidazo[4,5-*c*]quinoléin-1-yl]-2-méthylpropan-2-ol

resiquimod — 4-amino-2-(etoximetil)-α,α-dimetil-1*H*-imidazo[4,5-*c*]quinolina-1-etanol

$C_{17}H_{22}N_4O_2$



risarestatum

risarestat — (±)-5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione

risarestat — (5*RS*)-5-[3-éthoxy-4-(pentyloxy)phényl]thiazolidine-2,4-dione

risarestat

(±)-5-[3-etoxi-4-(pentiloxi)fenil]-2,4-tiazolidinadiona

$C_{16}H_{21}NO_4S$



rubitecanum

rubitecan

9-nitrocamptothecin

rubitécan

(4*S*)-4-éthyl-4-hydroxy-10-nitro-1,12-dihydro-14*H*-pyrano[3',4':6,7]= indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione

rubitecán

9-nitrocamptotecina

$C_{20}H_{15}N_3O_6$



sulamserodum

sulamserod

N-[2-[4-[2-[(8-amino-7-chloro-1,4-benzodioxan-5-yl)carbonyl]ethyl]piperidino]ethyl]methanesulfonamide

sulamsérod

N-[2-[4-[3-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-oxopropyl]pipéridin-1-yl]éthyl]méthanesulfonamide

sulamserod

N-[2-[4-[2-[(8-amino-7-cloro-1,4-benzodioxan-5-il)carbonil]etil]piperidino]= etil]metanosulfonamida

$C_{19}H_{28}ClN_3O_5S$



tanomastatum

tanomastat

(*S*)-3-[(4'-chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid

tanomastat

acide (2S)-4-(4'-chlorobiphényl-4-yl)-4-oxo-2-[(phénylsulfanyl)méthyl]= butanoïque

tanomastat

ácido (2S)-4-(4'-clorobifenil-4-il)-4-oxo-2-[(fenilsulfanilo)metil]butanoico

$C_{23}H_{19}ClO_3S$



tebipenemum

tebipenem

(+)-hydroxymethyl (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[1-(2-thiazolin-2-yl)-3-azetidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate, 2-pivalate

tébipénem

(+)-(4*R*,5*S*,6*S*)-3-[[1-(4,5-dihydrothiazol-2-yl)azétidin-3-yl]sulfanyl]-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylate de [(2,2-diméthylpropanoyl)oxy]méthyle

tebipenem

2-pivalato y (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hidroxietil]-4-metil-7-oxo-3-[[1-(2-tiazolin-2-il)-3-azetidinil]tio]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxilato de metileno

$C_{22}H_{31}N_3O_6S_2$



tenofovirum

tenofovir

[[(*R*)-2-(6-amino-9*H*-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid

ténofovir

acide [[(1*R*)-2-(6-amino-9*H*-purin-9-yl)-1-méthyléthoxy]méthyl]phosphonique

tenofovir

ácido [[(*R*)-2-(6-amino-9*H*-purin-9-il)-1-metiletoxi]metil]fosfónico

$C_9H_{14}N_5O_4P$



tiplimotidum

tiplimotide

D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phenylalanyl-L-alanyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonyl-L-prolinamide

tiplimotide

D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phénylalanyl-L-alanyl-L-asparaginyl-L-isoleucyl-L-valyl-L-thréonyl-L-prolyl-L-arginyl-L-thréonyl-L-prolinamide

tiplimotida

D-alanil-L-lisil-L-prolil-L-valil-L-valil-L-histidil-L-leucil-L-fenilalanil-L-alanil-L-asparaginil-L-isoleucil-L-valil-L-treonil-L-prolil-L-arginil-L-treonil-L-prolinamida

$C_{87}H_{143}N_{25}O_{20}$

D-Ala—Lys—Pro—Val—Val—His—Leu—Phe—Ala—Asn—
10
Ile—Val—Thr—Pro—Arg—Thr—Pro-NH_2

valrocemidum

valrocemide

N-(carbamoylmethyl)-2-propylvaleramide

valrocémide

N-(2-amino-2-oxoéthyl)-2-propylpentanamide

valrocemida

N-(carbamoilmetil)-2-propilvaleramida

$C_{10}H_{20}N_2O_2$



vardenafilum

vardenafil

1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-*f*]-*as*-triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethylpiperazine

vardénafil

2-[2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]phényl]-5-méthyl-7-propylimidazolo[5,1-*f*][1,2,4]triazin-4(3*H*)-one

vardenafil

1-[[3-(3,4-dihidro-5-metil-4-oxo-7-propilimidazo[5,1-*f*]-*as*-triazin-2-il)-4-etoxifenil]sulfonil]-4-etilpiperazina

$C_{23}H_{32}N_6O_4S$



vofopitantum

vofopitant (2*S*,3*S*)-3-[[2-methoxy-5-[5-(trifluoromethyl)-1*H*-tetrazol-1-yl]benzyl]amino]-2-phenylpiperidine

vofopitant (2*S*,3*S*)-*N*-[2-méthoxy-5-[5-(trifluorométhyl)-1*H*-tétrazol-1-yl]benzyl]-2-phénylpipéridin-3-amine

vofopitant (2*S*,3*S*)-3-[[2-metoxi-5-[5-(trifluorometil)-1*H*-tetrazol-1-il]bencil]amino]-2-fenilpiperidina

$C_{21}H_{23}F_3N_6O$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 43
Dénominations communes internationales recommandées (DCI Rec.): Liste 43
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 43
(WHO Drug Information, Vol. 14, No. 1, 2000)

p. 50 **eledoisinum**
eledoïsine

remplacer le nom par le suivant:
élédoïsine

p. 57 **idremcinalum**
idremcinal

remplacer le nom chimique par le suivant:
(2*R*,3*R*,4*S*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-5-éthyl-3,4-dihydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3-*C*-méthyl-3-*O*-méthyl-2,6-didésoxy-α-L-*ribo*-hexopyranosyl)oxy]-11-[[3-[méthyl(1-méthyléthyl)amino]-3,4,6-tridésoxy-β-D-*xylo*-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

p. 59 **lasofoxifenum**
lasofoxifène

remplacer le nom chimique par le suivant:
(-)-(5*R**,6*S**)-6-phényl-5-[4-[2-(pyrrolidin-1-yl)éthoxy]phényl]-5,6,7,8-tétrahydronaphtalén-2-ol

p. 64 **pimecrolimusum**
pimécrolimus

remplacer le nom chimique par le suivant:
(1*R*,9*S*,12*S*,13*R*,14*S*,17*R*,18*E*,21*S*,23*S*,24*R*,25*S*,27*R*)-12-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-chloro-3-méthoxycyclohexyl]-1-méthyléthényl]-17-éthyl-1,14-dihydroxy-23,25-diméthoxy-13,19,21,27-tétraméthyl-11,28-dioxa-4-azatricyclo[22.3.1.$0^{4,9}$]octacos-18-ène-2,3,10,16-tétrone

p. 66 **sarakalimum**
sarakalim

remplacer le nom chimique par le suivant:
N-[[2,2-diméthyl-4-(2-oxopyridin-1(2*H*)-yl)-6-(trifluorométhyl)-2*H*-1benzopyran-3-yl]méthyl]-*N*-hydroxyacétamide

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internatio-nales applicables aux substances pharmaceutiques* ont été publiés avec la liste 81 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sus-tancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacio-nales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.